Metabolic reprogramming in cholangiocarcinoma

被引:72
|
作者
Raggi, Chiara [1 ]
Taddei, Maria Letizia [1 ]
Rae, Colin [2 ]
Braconi, Chiara [2 ,3 ]
Marra, Fabio [1 ]
机构
[1] Univ Florence, Dept Expt & Clin Med, Cubo Ctr Polivalente 2,Viale Pieraccini 6, I-50139 Florence, Italy
[2] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland
[3] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
关键词
glycolysis; oxidative metabolism; mitochondria; fatty acids; IDH1/2; glutamine; cancer stem cells; mTOR; CD36; PGC1; alpha; methionine adenosyltransferases; fatty acid synthase; ISOCITRATE DEHYDROGENASE 1; PYRUVATE-KINASE M2; MUTANT IDH1; INTRAHEPATIC CHOLANGIOCARCINOMA; GENE-EXPRESSION; DUAL INHIBITOR; LIVER-CANCER; RISK-FACTORS; FATTY-ACID; PHASE-I;
D O I
10.1016/j.jhep.2022.04.038
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Metabolic reprogramming is a hallmark of cancer and allows tumour cells to meet the increased energy demands required for rapid proliferation, invasion, and metastasis. Indeed, many tumour cells acquire distinctive metabolic and bioenergetic features that enable them to survive in resource-limited conditions, mainly by harnessing alternative nutrients. Several recent studies have explored the metabolic plasticity of cancer cells with the aim of identifying new druggable targets, while therapeutic strategies to limit the access to nutrients have been successfully applied to the treatment of some tumours. Cholangiocarcinoma (CCA), a highly heterogeneous tumour, is the second most common form of primary liver cancer. It is characterised by resistance to chemotherapy and poor prognosis, with 5-year survival rates of below 20%. Deregulation of metabolic pathways have been described during the onset and progression of CCA. Increased aerobic glycolysis and glutamine anaplerosis provide CCA cells with the ability to generate biosynthetic intermediates. Other metabolic alterations involving carbohydrates, amino acids and lipids have been shown to sustain cancer cell growth and dissemination. In this review, we discuss the complex metabolic rewiring that occurs during CCA development and leads to unique nutrient addiction. The possible role of therapeutic interventions based on metabolic changes is also thoroughly discussed.
引用
收藏
页码:849 / 864
页数:16
相关论文
共 50 条
  • [41] Myocardial Metabolic Reprogramming in HFpEF
    Zihui Zhang
    Mingchu Sun
    Wenhua Jiang
    Lu Yu
    Chan Zhang
    Heng Ma
    [J]. Journal of Cardiovascular Translational Research, 2024, 17 : 121 - 132
  • [42] Metabolic reprogramming and cancer progression
    Faubert, Brandon
    Solmonson, Ashley
    DeBerardinis, Ralph J.
    [J]. SCIENCE, 2020, 368 (6487) : 152 - +
  • [43] Metabolic Reprogramming in Cardiovascular Diseases
    Juan Gao
    Yujiao Zhu
    Yihua Bei
    [J]. Journal of Cardiovascular Translational Research, 2024, 17 : 33 - 35
  • [44] Metabolic reprogramming in liver fibrosis
    Horn, Paul
    Tacke, Frank
    [J]. CELL METABOLISM, 2024, 36 (07)
  • [45] Metabolic disorders and the risk of cholangiocarcinoma
    Ghidini, Michele
    Ramai, Daryl
    Facciorusso, Antonio
    Singh, Jameel
    Tai, Waqqas
    Rijavec, Erika
    Galassi, Barbara
    Grossi, Francesco
    Indini, Alice
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (09) : 999 - 1007
  • [46] Metabolic reprogramming in renal cancer: Events of a metabolic disease
    Chakraborty, Samik
    Balan, Murugabaskar
    Sabarwal, Akash
    Choueiri, Toni K.
    Pal, Soumitro
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (01):
  • [47] Metabolic reprogramming: A novel metabolic model for pulmonary hypertension
    Liu, Xuhan
    Zhang, Liping
    Zhang, Weihua
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [48] Dysregulated metabolic enzymes and metabolic reprogramming in cancer cells
    Sreedhar, Annapoorna
    Zhao, Yunfeng
    [J]. BIOMEDICAL REPORTS, 2018, 8 (01) : 3 - 10
  • [49] Metabolic reprogramming and interventions in endometrial carcinoma
    Li, Jiajia
    Yang, Hongmei
    Zhang, Lingyi
    Zhang, Songling
    Dai, Yun
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2023, 161
  • [50] Nitric oxide and tumor metabolic reprogramming
    Lopez-Sanchez, Laura M.
    Aranda, Enrique
    Rodriguez-Ariza, Antonio
    [J]. BIOCHEMICAL PHARMACOLOGY, 2020, 176